Solvemed Group


With the primary focus in Parkinson’s disease, Solvemed Group leverages its proprietary machine learning technology to develop novel diagnostic-predictive digital biomarkers to enable first-in-class, accurate, early and cost-effective diagnostic and monitoring tools.

Focus: Diagnostics and drug discovery platform 

Team: Hugo Chrost and Michal Wlodarski




We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.